Choriorétinopathie séreuse centrale consecutive au vaccin à ARN messager BNT162b2

Translated title of the contribution: Central serous chorioretinopathy following the BNT162b2 mRNA vaccine

J. Hanhart, E. Roditi, L. M. Wasser, W. Barhoum, D. Zadok, K. Brosh

Research output: Contribution to journalArticlepeer-review


Background and purpose: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has accelerated vaccine development. The BNT162b2 messenger RNA (mRNA) vaccine is being administered worldwide. The purpose of this case series is to report a possible association between the BNT162b2 mRNA vaccine and Central serous chorioretinopathy (CSC). Although rare, CSC has been reported following the administration of anthrax, influenza and smallpox vaccines. Methods: Four individuals who developed CSC following the BNT162b2 mRNA vaccine were examined in our institution using multimodal imaging of the retina, and their demographic data were analyzed and compared to all the similar cases published to date. Results: Four patients (3 males, 1 female) between the ages of 35 and 65 presented with acute CSC (n = 3) and relapsed CSC (n = 1) within the first week following the administration of the BNT162b2 mRNA vaccine. Three individuals demonstrated hyper-reflective foci in the outer segments of the retina. Conclusions: The timing of the BNT162b2 mRNA vaccine administration relative to the development of CSC suggests a possible causal relationship. Further research is necessary to explore this possible association.

Translated title of the contributionCentral serous chorioretinopathy following the BNT162b2 mRNA vaccine
Original languageFrench
Pages (from-to)597-602
Number of pages6
JournalJournal Francais d'Ophtalmologie
Issue number6
StatePublished - Jun 2022
Externally publishedYes


  • BNT162b2 mRNA vaccine
  • COVID-19
  • Central serous chorioretinopathy
  • Pachychoroid
  • Serous retinal detachment
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Vaccination


Dive into the research topics of 'Central serous chorioretinopathy following the BNT162b2 mRNA vaccine'. Together they form a unique fingerprint.

Cite this